Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Case

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 31, 2016
Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's diseaseChristopher Carlson, Eric Siemers, Ann Hake, et al.
The Journal of Clinical Psychiatry|April 6, 2010
Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studiesMauricio Tohen, Michael Case, Madhukar H Trivedi, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|March 13, 2014
Association between clinical measures and florbetapir F18 PET neuroimaging in mild or moderate Alzheimer's disease dementiaMichael M Witte, Paula Trzepacz, Michael Case, et al.
Schizophrenia Research|April 15, 2011
Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trialsVirginia Stauffer, Michael Case, Sara Kollack-Walker, et al.
Psychiatry and Clinical Neurosciences|January 15, 2014
Safety and efficacy of olanzapine in the long-term treatment of Japanese patients with bipolar I disorder, depression: an integrated analysisHideaki Katagiri, Mauricio Tohen, David P McDonnell, et al.
BMC Psychiatry|May 16, 2013
Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled studyHideaki Katagiri, Mauricio Tohen, David P McDonnell, et al.
Journal of Psychiatric Research|June 15, 2010
Early symptom change and prediction of subsequent remission with olanzapine augmentation in divalproex-resistant bipolar mixed episodesJohn P Houston, Terence A Ketter, Michael Case, et al.
Neurobiology of Aging|August 20, 2013
Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementiaPaula T Trzepacz, Peng Yu, Jia Sun, et al.
Bipolar Disorders|September 12, 2007
Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depressionSanjay Dubé, Gary D Tollefson, Michael E Thase, et al.
The British Journal of Psychiatry : the Journal of Mental Science|August 25, 2012
Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depressionMauricio Tohen, David P McDonnell, Michael Case, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 31, 2016
Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's diseaseChristopher Carlson, Eric Siemers, Ann Hake, et al.
The Journal of Clinical Psychiatry|April 6, 2010
Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studiesMauricio Tohen, Michael Case, Madhukar H Trivedi, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|March 13, 2014
Association between clinical measures and florbetapir F18 PET neuroimaging in mild or moderate Alzheimer's disease dementiaMichael M Witte, Paula Trzepacz, Michael Case, et al.
Schizophrenia Research|April 15, 2011
Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trialsVirginia Stauffer, Michael Case, Sara Kollack-Walker, et al.
Psychiatry and Clinical Neurosciences|January 15, 2014
Safety and efficacy of olanzapine in the long-term treatment of Japanese patients with bipolar I disorder, depression: an integrated analysisHideaki Katagiri, Mauricio Tohen, David P McDonnell, et al.
BMC Psychiatry|May 16, 2013
Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled studyHideaki Katagiri, Mauricio Tohen, David P McDonnell, et al.
Journal of Psychiatric Research|June 15, 2010
Early symptom change and prediction of subsequent remission with olanzapine augmentation in divalproex-resistant bipolar mixed episodesJohn P Houston, Terence A Ketter, Michael Case, et al.
Neurobiology of Aging|August 20, 2013
Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementiaPaula T Trzepacz, Peng Yu, Jia Sun, et al.
Bipolar Disorders|September 12, 2007
Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depressionSanjay Dubé, Gary D Tollefson, Michael E Thase, et al.
The British Journal of Psychiatry : the Journal of Mental Science|August 25, 2012
Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depressionMauricio Tohen, David P McDonnell, Michael Case, et al.
Pageof 4